Demographic and chronic GVHD characteristics at study entry
Characteristic . | Value . |
|---|---|
| Sample size, no. | 21 |
| Median age, y (range) | 42 (21-62) |
| Sex, no. (%) | |
| Male | 10 (48) |
| Female | 11 (52) |
| Time after transplantation, mo (range) | 23.3 (8.5-114.6) |
| Time after chronic GVHD diagnosis, mo (range) | 13.8 (2.9-82.0) |
| Stem cell donor, no. (%) | |
| HLA-matched sibling | 14 (67) |
| HLA-matched unrelated | 7 (33) |
| Stem cell source, no. (%) | |
| Peripheral blood stem cell | 15 (71) |
| Bone marrow | 6 (29) |
| Conditioning regimen, no. (%) | |
| Myeloablative* | 16 (76) |
| Nonmyeloablative† | 5 (24) |
| Acute GVHD prophylaxis, no. (%) | |
| Tacrolimus-methotrexate | 1 (5) |
| Tacrolimus-sirolimus-methotrexate | 4 (19) |
| Tacrolimus-sirolimus | 4 (19) |
| T-cell depletion with or without other | 7 (33) |
| Cyclosporine with or without methotrexate and/or other | 5 (24) |
| Prior acute GVHD, no. (%) | |
| Grades 0-I | 16 (76) |
| Grades II-IV | 5 (24) |
| End-organ involvement, no. (%) | |
| Skin | 17 (81) |
| Musculoskeletal | 12 (57) |
| Eye | 8 (38) |
| Oral mucosa | 7 (33) |
| Liver alone | 1 (5) |
| Immunosuppression at study entry, no. (%) | |
| Steriod alone | 4 (19) |
| Steroid with calcineurin inhibitor | 4 (19) |
| Steroid with calcineurin inhibitor and other | 3 (14) |
| Steroid with other | 9 (43) |
| Calcineurin inhibitor alone | 1 (5) |
Characteristic . | Value . |
|---|---|
| Sample size, no. | 21 |
| Median age, y (range) | 42 (21-62) |
| Sex, no. (%) | |
| Male | 10 (48) |
| Female | 11 (52) |
| Time after transplantation, mo (range) | 23.3 (8.5-114.6) |
| Time after chronic GVHD diagnosis, mo (range) | 13.8 (2.9-82.0) |
| Stem cell donor, no. (%) | |
| HLA-matched sibling | 14 (67) |
| HLA-matched unrelated | 7 (33) |
| Stem cell source, no. (%) | |
| Peripheral blood stem cell | 15 (71) |
| Bone marrow | 6 (29) |
| Conditioning regimen, no. (%) | |
| Myeloablative* | 16 (76) |
| Nonmyeloablative† | 5 (24) |
| Acute GVHD prophylaxis, no. (%) | |
| Tacrolimus-methotrexate | 1 (5) |
| Tacrolimus-sirolimus-methotrexate | 4 (19) |
| Tacrolimus-sirolimus | 4 (19) |
| T-cell depletion with or without other | 7 (33) |
| Cyclosporine with or without methotrexate and/or other | 5 (24) |
| Prior acute GVHD, no. (%) | |
| Grades 0-I | 16 (76) |
| Grades II-IV | 5 (24) |
| End-organ involvement, no. (%) | |
| Skin | 17 (81) |
| Musculoskeletal | 12 (57) |
| Eye | 8 (38) |
| Oral mucosa | 7 (33) |
| Liver alone | 1 (5) |
| Immunosuppression at study entry, no. (%) | |
| Steriod alone | 4 (19) |
| Steroid with calcineurin inhibitor | 4 (19) |
| Steroid with calcineurin inhibitor and other | 3 (14) |
| Steroid with other | 9 (43) |
| Calcineurin inhibitor alone | 1 (5) |